

Jeffrey Aronson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7726528/publications.pdf>

Version: 2024-02-01

342
papers

19,476
citations

24978

57
h-index

12910

131
g-index

368
all docs

368
docs citations

368
times ranked

22878
citing authors

#	ARTICLE	IF	CITATIONS
1	Adverse drug reactions: definitions, diagnosis, and management. <i>Lancet, The</i> , 2000, 356, 1255-1259.	6.3	2,294
2	The SCARE Statement: Consensus-based surgical case report guidelines. <i>International Journal of Surgery</i> , 2016, 34, 180-186.	1.1	1,585
3	A new taxonomy for describing and defining adherence to medications. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 691-705.	1.1	1,308
4	STROCCS 2019 Guideline: Strengthening the reporting of cohort studies in surgery. <i>International Journal of Surgery</i> , 2019, 72, 156-165.	1.1	1,248
5	CARE guidelines for case reports: explanation and elaboration document. <i>Journal of Clinical Epidemiology</i> , 2017, 89, 218-235.	2.4	993
6	Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2016, 30, 495-553.	2.0	755
7	The STROCCS statement: Strengthening the Reporting of Cohort Studies in Surgery. <i>International Journal of Surgery</i> , 2017, 46, 198-202.	1.1	727
8	Evaluation and stages of surgical innovations. <i>Lancet, The</i> , 2009, 374, 1089-1096.	6.3	492
9	Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. <i>BMC Medicine</i> , 2016, 14, 10.	2.3	384
10	Preferred reporting of case series in surgery; the PROCESS guidelines. <i>International Journal of Surgery</i> , 2016, 36, 319-323.	1.1	351
11	Medication errors: definitions and classification. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 599-604.	1.1	272
12	Biomarkers and surrogate endpoints. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 491-494.	1.1	225
13	Clarification of Terminology in Drug Safety. <i>Drug Safety</i> , 2005, 28, 851-870.	1.4	221
14	Joining the DoTS: new approach to classifying adverse drug reactions. <i>BMJ: British Medical Journal</i> , 2003, 327, 1222-1225.	2.4	217
15	Clarification of Terminology in Medication Errors. <i>Drug Safety</i> , 2006, 29, 1011-1022.	1.4	207
16	The Need for Randomization in Animal Trials: An Overview of Systematic Reviews. <i>PLoS ONE</i> , 2014, 9, e98856.	1.1	199
17	Biomarkers—A General Review. <i>Current Protocols in Pharmacology</i> , 2017, 76, 9.23.1-9.23.17.	4.0	196
18	Compliance, concordance, adherence. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 383-384.	1.1	192

#	ARTICLE	IF	CITATIONS
19	Overdiagnosis: what it is and what it isn't. BMJ Evidence-Based Medicine, 2018, 23, 1-3.	1.7	191
20	Medication errors: what they are, how they happen, and how to avoid them. QJM - Monthly Journal of the Association of Physicians, 2009, 102, 513-521.	0.2	188
21	Anecdotes that provide definitive evidence. BMJ: British Medical Journal, 2006, 333, 1267-1269.	2.4	162
22	Defining "nutraceuticals": neither nutritious nor pharmaceutical. British Journal of Clinical Pharmacology, 2017, 83, 8-19.	1.1	158
23	Low-Dose Adrenaline, Promethazine, and Hydrocortisone in the Prevention of Acute Adverse Reactions to Antivenom following Snakebite: A Randomised, Double-Blind, Placebo-Controlled Trial. PLoS Medicine, 2011, 8, e1000435.	3.9	154
24	Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.. Gut, 1982, 23, 1081-1087.	6.1	144
25	Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet, The, 2003, 361, 1935-1938.	6.3	125
26	All-Cause and Cardiovascular Mortality in Middle-Aged People With Type 2 Diabetes Compared With People Without Diabetes in a Large U.K. Primary Care Database. Diabetes Care, 2013, 36, 2366-2371.	4.3	121
27	Defining "Signal" and its Subtypes in Pharmacovigilance Based on a Systematic Review of Previous Definitions. Drug Safety, 2009, 32, 99-110.	1.4	119
28	The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.. British Journal of Clinical Pharmacology, 1982, 13, 523-528.	1.1	116
29	Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. BMC Medicine, 2016, 14, 191.	2.3	113
30	Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. British Journal of Clinical Pharmacology, 1996, 42, 423-429.	1.1	106
31	Catalogue of bias: attrition bias. BMJ Evidence-Based Medicine, 2018, 23, 21-22.	1.7	101
32	Clinical Pharmacokinetics of Digoxin 1980. Clinical Pharmacokinetics, 1980, 5, 137-149.	1.6	98
33	Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Medical Research Methodology, 2001, 1, 7.	1.4	95
34	Rare diseases and orphan drugs. British Journal of Clinical Pharmacology, 2006, 61, 243-245.	1.1	95
35	Temporal trends in use of tests in UK primary care, 2000-15: retrospective analysis of 250 million tests. BMJ: British Medical Journal, 2018, 363, k4666.	2.4	91
36	Redefining rapid reviews: a flexible framework for restricted systematic reviews. BMJ Evidence-Based Medicine, 2018, 23, 201-203.	1.7	90

#	ARTICLE	IF	CITATIONS
37	Anecdotes as evidence. <i>BMJ: British Medical Journal</i> , 2003, 326, 1346-1346.	2.4	89
38	Drugs and the renin-angiotensin system in covid-19. <i>BMJ, The</i> , 2020, 369, m1313.	3.0	89
39	Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. <i>BMJ, The</i> , 2021, 374, n1537.	3.0	88
40	Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. <i>Critical Reviews in Toxicology</i> , 2016, 46, 477-489.	1.9	86
41	Old drugs – new uses. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 563-565.	1.1	85
42	Case reports of suspected adverse drug reactions – systematic literature survey of follow-up. <i>BMJ: British Medical Journal</i> , 2006, 332, 335-339.	2.4	84
43	In defence of polypharmacy. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 119-120.	1.1	83
44	Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 423-429.	1.1	82
45	Evidence-based mechanistic reasoning. <i>Journal of the Royal Society of Medicine</i> , 2010, 103, 433-441.	1.1	81
46	Overtesting and undertesting in primary care: a systematic review and meta-analysis. <i>BMJ Open</i> , 2018, 8, e018557.	0.8	80
47	Inhibition of Na ⁺ /K ⁺ -ATPase may be one mechanism contributing to potassium efflux and cell shrinkage in CD95-induced apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2000, 5, 153-163.	2.2	77
48	Gold Standards in Pharmacovigilance. <i>Drug Safety</i> , 2007, 30, 645-655.	1.4	77
49	Medication errors, worse than a crime. <i>Lancet, The</i> , 2000, 355, 947-948.	6.3	67
50	Comparison of essential medicines lists in 137 countries. <i>Bulletin of the World Health Organization</i> , 2019, 97, 394-404C.	1.5	67
51	What is a clinical trial?. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 1-3.	1.1	65
52	Reduced Salt Intake for Heart Failure. <i>JAMA Internal Medicine</i> , 2018, 178, 1693.	2.6	65
53	Trials of transvaginal mesh devices for pelvic organ prolapse: a systematic database review of the US FDA approval process. <i>BMJ Open</i> , 2017, 7, e017125.	0.8	64
54	A NEW TAXONOMY FOR DESCRIBING AND DEFINING ADHERENCE TO MEDICATIONS. <i>British Journal of Clinical Pharmacology</i> , 2011, 73, no-no.	1.1	63

#	ARTICLE	IF	CITATIONS
55	Standardization of symbols in clinical pharmacology. <i>European Journal of Clinical Pharmacology</i> , 1988, 35, 1-7.	0.8	62
56	The acute changes seen in cardiac glycoside receptor sites, ⁸⁶ Rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy.. <i>British Journal of Clinical Pharmacology</i> , 1979, 8, 135-142.	1.1	61
57	Preventability of Drug-Related Harms – Part I. <i>Drug Safety</i> , 2010, 33, 985-994.	1.4	61
58	Tranlycypromine (–Parnate™) overdose: measurement of tranlycypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. <i>Psychological Medicine</i> , 1979, 9, 377-382.	2.7	60
59	Poor medication adherence in clinical trials: consequences and solutions. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 149-150.	21.5	58
60	ALTERED DISTRIBUTION OF DIGOXIN IN RENAL FAILURE – A CAUSE OF DIGOXIN TOXICITY?. <i>British Journal of Clinical Pharmacology</i> , 1976, 3, 1045-1051.	1.1	55
61	Unlicensed and off-label uses of medicines: definitions and clarification of terminology. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2615-2625.	1.1	55
62	Adverse events in people taking macrolide antibiotics versus placebo for any indication. <i>The Cochrane Library</i> , 2019, 2019, CD011825.	1.5	55
63	Potassium channels in nervous tissue. <i>Biochemical Pharmacology</i> , 1992, 43, 11-14.	2.0	54
64	Autopathography: the patient's tale. <i>BMJ: British Medical Journal</i> , 2000, 321, 1599-1602.	2.4	54
65	A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 616-621.	1.1	54
66	"Where name and image meet" – the argument for "adrenaline". <i>BMJ: British Medical Journal</i> , 2000, 320, 506-509.	2.4	53
67	Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan.. <i>British Journal of Clinical Pharmacology</i> , 1980, 10, 603-610.	1.1	49
68	Paradoxical and Bidirectional Drug Effects. <i>Drug Safety</i> , 2012, 35, 1.	1.4	49
69	Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. <i>BMC Medicine</i> , 2015, 13, 26.	2.3	48
70	Medication errors: problems and recommendations from a consensus meeting. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 592-598.	1.1	47
71	Defining rewardable innovation in drug therapy. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 253-254.	21.5	47
72	Medical Devices: Definition, Classification, and Regulatory Implications. <i>Drug Safety</i> , 2020, 43, 83-93.	1.4	47

#	ARTICLE	IF	CITATIONS
73	Quantifying the effects of diuretics and β -adrenoceptor blockers on glycaemic control in diabetes mellitus – a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 733-743.	1.1	46
74	Medication errors resulting from the confusion of drug names. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 167-172.	1.0	45
75	Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response.. <i>British Journal of Clinical Pharmacology</i> , 1977, 4, 213-221.	1.1	44
76	Altered in vitro adaptive responses of lymphocyte Na^+ , K^+ -ATPase in patients with manic depressive psychosis. <i>Journal of Affective Disorders</i> , 1991, 21, 199-206.	2.0	44
77	Adverse drug reactions: keeping up to date. <i>Fundamental and Clinical Pharmacology</i> , 2002, 16, 49-56.	1.0	44
78	Rational prescribing, appropriate prescribing. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 229-230.	1.1	42
79	Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. <i>Lancet, The</i> , 1998, 352, 1590-1593.	6.3	41
80	A manifesto for clinical pharmacology from principles to practice. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 3-13.	1.1	41
81	NICE and new: appraising innovation. <i>BMJ: British Medical Journal</i> , 2010, 340, b5493-b5493.	2.4	41
82	Indications for the Measurement of Plasma Digoxin Concentrations. <i>Drugs</i> , 1983, 26, 230-242.	4.9	40
83	Balanced prescribing. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 629-632.	1.1	39
84	Classifying drug interactions. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 343-344.	1.1	38
85	Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2114-2122.	1.1	37
86	Changes in cardiac glycoside receptor sites, rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation.. <i>British Journal of Clinical Pharmacology</i> , 1979, 8, 125-134.	1.1	35
87	ABC of monitoring drug therapy. Patient compliance.. <i>BMJ: British Medical Journal</i> , 1992, 305, 1009-1011.	2.4	35
88	Prolonged half-life of verapamil in a case of overdose: implications for therapy.. <i>British Journal of Clinical Pharmacology</i> , 1995, 39, 680-683.	1.1	35
89	EIDOS. <i>Drug Safety</i> , 2010, 33, 15-23.	1.4	35
90	Structural requirements for voltage-dependent block of muscle sodium channels by phenol derivatives. <i>British Journal of Pharmacology</i> , 2001, 132, 1916-1924.	2.7	34

#	ARTICLE	IF	CITATIONS
91	Preventability of Drug-Related Harms – Part II. Drug Safety, 2010, 33, 995-1002.	1.4	34
92	Transdermal hyoscine (scopolamine) and postoperative vomiting. Anaesthesia, 1986, 41, 1-3.	1.8	33
93	Summarising good practice guidelines for data extraction for systematic reviews and meta-analysis. BMJ Evidence-Based Medicine, 2021, 26, 88-90.	1.7	33
94	The characteristics of the binding of 12 ^α [3H]digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy.. British Journal of Clinical Pharmacology, 1979, 8, 115-124.	1.1	31
95	Distinguishing Hazards and Harms, Adverse Drug Effects and Adverse Drug Reactions. Drug Safety, 2013, 36, 147-153.	1.4	31
96	Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions. Journal of Evaluation in Clinical Practice, 2005, 11, 195-208.	0.9	30
97	The problem of look-alike, sound-alike name errors: Drivers and solutions. British Journal of Clinical Pharmacology, 2021, 87, 386-394.	1.1	30
98	Balanced prescribing – principles and challenges. British Journal of Clinical Pharmacology, 2012, 74, 566-572.	1.1	29
99	Key concepts for making informed choices. Nature, 2019, 572, 303-306.	13.7	28
100	Naltrexone–bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. British Journal of Clinical Pharmacology, 2020, 86, 646-667.	1.1	28
101	An improved model for the binding of lidocaine and structurally related local anaesthetics to fast-inactivated voltage-operated sodium channels, showing evidence of cooperativity. British Journal of Pharmacology, 2004, 141, 47-54.	2.7	27
102	Risk perception in drug therapy. British Journal of Clinical Pharmacology, 2006, 62, 135-137.	1.1	27
103	An agenda for UK clinical pharmacology: Research priorities in biomarkers and surrogate endpoints. British Journal of Clinical Pharmacology, 2012, 73, 900-907.	1.1	27
104	An agenda for UK clinical pharmacology: Monitoring drug therapy. British Journal of Clinical Pharmacology, 2012, 73, 917-923.	1.1	27
105	Defining –Surveillance–™ in Drug Safety. Drug Safety, 2012, 35, 347-357.	1.4	26
106	Pharmacokinetic investigation of the interaction of azapropazone with phenytoin.. British Journal of Clinical Pharmacology, 1983, 15, 727-734.	1.1	25
107	Evidence of Misclassification of Drug–Event Associations Classified as Gold Standard –Negative Controls–™ by the Observational Medical Outcomes Partnership (OMOP). Drug Safety, 2016, 39, 421-432.	1.4	25
108	Medication errors resulting from the confusion of drug names. Expert Opinion on Drug Safety, 2004, 3, 167-72.	1.0	25

#	ARTICLE	IF	CITATIONS
109	Polypharmacy, appropriate and inappropriate. <i>British Journal of General Practice</i> , 2006, 56, 484-5.	0.7	25
110	Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution.. <i>British Journal of Clinical Pharmacology</i> , 1977, 4, 223-227.	1.1	24
111	Monitoring digoxin therapy: III. How useful are the nomograms?. <i>British Journal of Clinical Pharmacology</i> , 1978, 5, 55-64.	1.1	24
112	Measurement of specific [³ H]ouabain binding to different types of human leucocytes.. <i>British Journal of Clinical Pharmacology</i> , 1984, 18, 153-161.	1.1	24
113	Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.. <i>Gut</i> , 1992, 33, 1353-1357.	6.1	24
114	Clinical pharmacology – providing tools and expertise for translational medicine. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 154-157.	1.1	24
115	Susceptibility to adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2205-2212.	1.1	24
116	Confusion Over Similar Drug Names Problems and Solutions. <i>Drug Safety</i> , 1995, 12, 155-160.	1.4	23
117	The use of mechanistic evidence in drug approval. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 1166-1176.	0.9	23
118	Clinical Pharmacokinetics of Cardiac Glycosides in Patients with Renal Dysfunction. <i>Clinical Pharmacokinetics</i> , 1983, 8, 155-178.	1.6	22
119	Communicating information about drug interactions. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 637-639.	1.1	22
120	Global, regional, and national consumption of controlled opioids: a cross-sectional study of 214 countries and non-metropolitan territories. <i>British Journal of Pain</i> , 2022, 16, 34-40.	0.7	22
121	The Effect of Lithium on Cation Transport Measured in vivo in Patients Suffering from Bipolar Affective Illness. <i>British Journal of Psychiatry</i> , 1989, 155, 504-510.	1.7	21
122	Concentration-effect and dose-response relations in clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 255-257.	1.1	21
123	Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 52-55.	1.1	21
124	Drugs for rare disorders. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1607-1613.	1.1	21
125	Practice variation in the use of tests in UK primary care: a retrospective analysis of 16 million tests performed over 3.3 million patient years in 2015/16. <i>BMC Medicine</i> , 2018, 16, 229.	2.3	21
126	Post-marketing drug withdrawals: Pharmacovigilance success, regulatory problems. <i>Therapie</i> , 2017, 72, 555-561.	0.6	20

#	ARTICLE	IF	CITATIONS
127	The upregulation of Na ⁺ ,K ⁺ -ATPase pump numbers in lymphocytes from the first-degree unaffected relatives of patients with manic depressive psychosis in response to in vitro lithium and sodium ethacrynate. <i>Journal of Affective Disorders</i> , 1995, 34, 33-39.	2.0	19
128	Adverse drug reactions ? no farewell to harms. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 131-135.	1.1	19
129	Something New Every Day. <i>Journal of Ambulatory Care Management</i> , 2008, 31, 65-68.	0.5	19
130	From prescription-only to over-the-counter medicines ('PoM to P'): time for an intermediate category. <i>British Medical Bulletin</i> , 2009, 90, 63-69.	2.7	19
131	The law of mass action and the pharmacological concentrationâ€effect curve: resolving the paradox of apparently nonâ€doseâ€related adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 56-61.	1.1	19
132	Block of voltage-operated sodium channels by 2,6-dimethylphenol, a structural analogue of lidocaine's aromatic tail. <i>British Journal of Pharmacology</i> , 2002, 137, 285-293.	2.7	18
133	Checklist for standardized reporting of drugâ€drug interaction management guidelines. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 313-318.	0.8	18
134	Shortâ€and mediumâ€term effects of light to moderate alcohol intake on glycaemic control in diabetes mellitus: a systematic review and metaâ€analysis of randomized trials. <i>Diabetic Medicine</i> , 2017, 34, 604-611.	1.2	18
135	Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 63-72.	1.0	18
136	Relation between opioid consumption and inclusion of opioids in 137 national essential medicines lists. <i>BMJ Global Health</i> , 2020, 5, e003563.	2.0	18
137	Deaths attributed to the use of medications purchased online. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 60-64.	1.7	18
138	DIGOXIN THERAPY: TEXTBOOKS, THEORY AND PRACTICE. <i>British Journal of Clinical Pharmacology</i> , 1976, 3, 639-648.	1.1	17
139	Medication errors: EMERGING solutions. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 589-591.	1.1	17
140	A Strategy for Regulatory Action When New Adverse Effects of a Licensed Product Emerge. <i>Drug Safety</i> , 2009, 32, 91-98.	1.4	17
141	What do clinical pharmacologists do? A questionnaire survey of senior UK clinical pharmacologists. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 161-169.	1.1	17
142	Artificial Intelligence in Pharmacovigilance: An Introduction to Terms, Concepts, Applications, and Limitations. <i>Drug Safety</i> , 2022, 45, 407-418.	1.4	17
143	Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients' own erythrocytes during glycoside therapy. <i>Klinische Wochenschrift</i> , 1981, 59, 1323-1332.	0.6	16
144	Forbidden fruit. <i>Nature Medicine</i> , 2001, 7, 29-30.	15.2	16

#	ARTICLE	IF	CITATIONS
145	Over-the-counter medicines. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 231-234.	1.1	16
146	National differences in publishing papers on adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 108-111.	1.1	16
147	Plagiarism “ please don’t copy. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 403-405.	1.1	16
148	Clinical pharmacology and therapeutics in the UK “ a great instauration. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 111-117.	1.1	16
149	Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy. <i>PLoS ONE</i> , 2011, 6, e18578.	1.1	16
150	Structural features of phenol derivatives determining potency for activation of chloride currents via $\alpha 1$ homomeric and $\alpha 1 \beta 2$ heteromeric glycine receptors. <i>British Journal of Pharmacology</i> , 2005, 145, 916-925.	2.7	15
151	Adverse events in patients taking macrolide antibiotics versus placebo for any indication. <i>The Cochrane Library</i> , 0, , .	1.5	15
152	A word about evidence: “rapid reviews” or “restricted reviews”? <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 204-205.	1.7	15
153	Patient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names. <i>PLoS ONE</i> , 2015, 10, e0145431.	1.1	15
154	Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity. <i>Drug Safety</i> , 2022, 45, 137-144.	1.4	15
155	The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific $[3H]$ ouabain binding to human lymphocytes after incubation for 3 days.. <i>British Journal of Clinical Pharmacology</i> , 1986, 22, 275-279.	1.1	14
156	ABC of monitoring drug therapy. Cyclosporin.. <i>BMJ: British Medical Journal</i> , 1992, 305, 1491-1494.	2.4	14
157	Clinical Pharmacology: Past, Present, and Future. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 647-649.	1.1	14
158	Changing beta-blockers in heart failure: when is a class not a class?. <i>British Journal of General Practice</i> , 2008, 58, 387-389.	0.7	14
159	Medical eponyms: taxonomies, natural history, and the evidence. <i>BMJ, The</i> , 2014, 349, g7586-g7586.	3.0	14
160	Medication errors detected in non-traditional databases: types of errors in methotrexate dosing as listed in four different Danish registers. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1375-1379.	0.8	14
161	Inhibiting the proton pump: mechanisms, benefits, harms, and questions. <i>BMC Medicine</i> , 2016, 14, 172.	2.3	14
162	Diagnostic test guidelines based on high-quality evidence had greater rates of adherence: a meta-epidemiological study. <i>Journal of Clinical Epidemiology</i> , 2018, 103, 40-50.	2.4	14

#	ARTICLE	IF	CITATIONS
163	Sales of Over-the-Counter Products Containing Codeine in 31 Countries, 2013â€“2019: A Retrospective Observational Study. <i>Drug Safety</i> , 2022, 45, 237-247.	1.4	14
164	Drug interactions-information, education, and the British National Formulary. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 371-372.	1.1	13
165	Coronersâ€™ concerns to prevent harms: a series of coronersâ€™ case reports to serve patient safety and educate the public, clinicians and policy-makers. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 37-38.	1.7	13
166	Pycnodysostosis and the making of an artist. <i>Gene</i> , 2015, 555, 59-62.	1.0	12
167	Variation in diagnostic test requests and outcomes: a preliminary metric for OpenPathology.net. <i>Scientific Reports</i> , 2018, 8, 4752.	1.6	12
168	Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e030596.	0.8	12
169	Patent medicines and secret remedies. <i>BMJ: British Medical Journal</i> , 2009, 339, b5415-b5415.	2.4	12
170	Commentary: Open access publishing: too much oxygen?. <i>BMJ: British Medical Journal</i> , 2005, 330, 759.1.	2.4	11
171	The NSAID roller coaster: more about rofecoxib. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 257-259.	1.1	11
172	How similar are biosimilars?. <i>BMJ, The</i> , 2016, 353, i2721.	3.0	11
173	Trends in kidney function testing in UK primary care since the introduction of the quality and outcomes framework: a retrospective cohort study using CPRD. <i>BMJ Open</i> , 2019, 9, e028062.	0.8	11
174	Crisis in the supply of medicines. <i>BMJ: British Medical Journal</i> , 2019, 367, l5841.	2.4	11
175	Single screening or double screening for study selection in systematic reviews?. <i>BMJ Evidence-Based Medicine</i> , 2020, 25, 149-150.	1.7	11
176	Deaths from cardiovascular disease involving anticoagulants: a systematic synthesis of coronersâ€™ case reports. <i>BJGP Open</i> , 2022, 6, BJGPO.2021.0150.	0.9	11
177	The pharmacokinetics of L-tryptophan following its intravenous and oral administration.. <i>British Journal of Clinical Pharmacology</i> , 1985, 20, 317-321.	1.1	10
178	Cation transport abnormalities in vivo in untreated essential hypertension. <i>Clinical Science</i> , 1986, 70, 611-616.	1.8	10
179	Antibiotics policies in the developing world. <i>European Journal of Clinical Pharmacology</i> , 1991, 41, 85-7.	0.8	10
180	Iatrogenic chest pain: a case of 5-fluorouracil cardiotoxicity. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1996, 89, 953-956.	0.2	10

#	ARTICLE	IF	CITATIONS
181	Voltage-dependent blockade of normal and mutant muscle sodium channels by benzylalcohol. <i>British Journal of Pharmacology</i> , 2000, 130, 1321-1330.	2.7	10
182	On the waterfront - the breadth and depth of clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 693-694.	1.1	10
183	Time to abandon the term "patient concordance". <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 711-713.	1.1	10
184	What is a "complex systematic review"? Criteria, definition, and examples. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 127-130.	1.7	10
185	Prescribing biosimilars. <i>BMJ: British Medical Journal</i> , 2018, 362, k3141.	2.4	10
186	Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme-inducing antibiotics and hormonal contraceptives. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 112-113.	1.7	10
187	Oral hormone pregnancy tests and the risks of congenital malformations: a systematic review and meta-analysis. <i>F1000Research</i> , 2018, 7, 1725.	0.8	10
188	Biomarkers and Surrogate Endpoints in Monitoring Therapeutic Interventions. , 0, , 48-62.		9
189	Defining Aspects of Mechanisms: Evidence-Based Mechanism (Evidence for a Mechanism), Mechanism-Based Evidence (Evidence from a Mechanism), and Mechanistic Reasoning. <i>Boston Studies in the Philosophy and History of Science</i> , 2020, , 3-38.	0.4	9
190	What's in a brand name?. <i>BMJ: British Medical Journal</i> , 1994, 308, 1140-1141.	2.4	9
191	The Measurement of Transmembrane Cation Transportin vivo in Acute Manic Illness. <i>British Journal of Psychiatry</i> , 1989, 155, 501-504.	1.7	8
192	On Being 30. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 1-5.	1.1	8
193	Prescribing statins. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 457-458.	1.1	8
194	Drug development: more science, more education. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 377-378.	1.1	8
195	Ten essential papers for the practice of evidence-based medicine. <i>BMJ Evidence-Based Medicine</i> , 2017, 22, 202-204.	1.7	8
196	The use of mechanistic reasoning in assessing coronavirus interventions. <i>Journal of Evaluation in Clinical Practice</i> , 2021, 27, 684-693.	0.9	8
197	The Oxford Catalogue of Opioids: A systematic synthesis of opioid drug names and their pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3790-3812.	1.1	8
198	When I use a word Listening to the patient. <i>BMJ, The</i> , 2022, 376, o646.	3.0	8

#	ARTICLE	IF	CITATIONS
199	Preventable deaths from SARS-CoV-2 in England and Wales: a systematic case series of coroners'™ reports during the COVID-19 pandemic. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 296-304.	1.7	8
200	The role of the Na ⁺ ,K ⁺ -ATPase in the regulation of vascular smooth-muscle contractility, and its relationship to essential hypertension. <i>Biochemical Society Transactions</i> , 1984, 12, 943-945.	1.6	7
201	Intravenous strontium gluconate as a kinetic marker for calcium in healthy volunteers.. <i>British Journal of Clinical Pharmacology</i> , 1991, 31, 423-427.	1.1	7
202	Increase in Na ⁺ /K ⁺ pump numbers in vivo in healthy volunteers taking oral lithium carbonate and further upregulation in response to lithium in vitro.. <i>British Journal of Clinical Pharmacology</i> , 1992, 34, 535-540.	1.1	7
203	Modelling circadian variation in the pharmacokinetics of non-steroidal anti-inflammatory drugs. <i>European Journal of Clinical Pharmacology</i> , 1993, 45, 357-61.	0.8	7
204	“Collaborative care” is preferable to “patient centred care”. <i>BMJ, The</i> , 2016, 353, i2926.	3.0	7
205	Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification. <i>Drug Safety</i> , 2017, 40, 431-441.	1.4	7
206	Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950-1980). <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1668-1685.	1.1	7
207	Withdrawn medicines included in the essential medicines lists of 136 countries. <i>PLoS ONE</i> , 2019, 14, e0225429.	1.1	7
208	Glycosides of plants and men. <i>Medical Journal of Australia</i> , 1986, 144, 505-506.	0.8	6
209	A study of the transport of lithium across the erythrocyte membrane in vivo and of the effects of the ion transport inhibitors digoxin and dipyridamole.. <i>British Journal of Clinical Pharmacology</i> , 1989, 27, 749-756.	1.1	6
210	The Diagnosis of Art: Arthrogyriposis and Ribera's The Clubfoot. <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 321-322.	1.1	6
211	The diagnosis of art: Caravaggio's jaundiced Bacchus. <i>Journal of the Royal Society of Medicine</i> , 2007, 100, 429-430.	1.1	6
212	The UK's NHS and pharma: need for more clinical pharmacologists. <i>Lancet, The</i> , 2009, 373, 1251-1252.	6.3	6
213	A Systematic Review and Empirical Analysis of the Relation Between Dose and Duration of Drug Action. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 17-26.	1.0	6
214	An agenda for UK clinical pharmacology: From basic to clinical neuropharmacology: targetophilia or pharmacodynamics?. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 959-967.	1.1	6
215	Nominal ISOMERs (Incorrect Spellings Of Medicines Eluding Researchers)“variants in the spellings of drug names in PubMed: a database review. <i>BMJ, The</i> , 2016, 355, i4854.	3.0	6
216	Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin. <i>Statistical Methods in Medical Research</i> , 2018, 27, 564-578.	0.7	6

#	ARTICLE	IF	CITATIONS
217	A systematic literature review of LASA error interventions. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 336-351.	1.1	6
218	Medicines regulation and clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 569-570.	1.1	5
219	One hundred years of atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 345-346.	1.1	5
220	Publishing Histories of Adverse Reactions to Medicaments Anecdotally. <i>Drug Safety</i> , 2008, 31, 355-356.	1.4	5
221	Examining the “psychopharmacology revolution” (1950–1980) through the advertising of psychoactive drugs in the <i>British Medical Journal</i> . <i>Journal of Psychopharmacology</i> , 2018, 32, 1056-1066.	2.0	5
222	Live long and prosper: a mass strategy for treating the factors associated with ischaemic heart disease and stroke. <i>Journal of Medical Screening</i> , 2004, 11, 1-2.	1.1	5
223	When I use a word . . . The Precautionary Principle: a brief history. <i>BMJ</i> , The, 2021, 375, n3059.	3.0	5
224	Penicillin. <i>European Journal of Clinical Pharmacology</i> , 1992, 42, 1-9.	0.8	4
225	Nurse prescribers & reporters. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 585-587.	1.1	4
226	Littluns and biguns. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 117-118.	1.1	4
227	Adjusting therapeutic dosage regimens to optimise the balance of benefit to harm. <i>Clinical Medicine</i> , 2005, 5, 16-19.	0.8	4
228	Metameta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 117-119.	1.1	4
229	Monitoring therapy. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 229-230.	1.1	4
230	The Diagnosis of Art: exophthalmos--Gustave Dore's ogre. <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 421-421.	1.1	4
231	Give a drug a good name. <i>Lancet</i> , The, 2007, 369, 1326-1328.	6.3	4
232	Reducing prescription errors. <i>Lancet</i> , The, 2010, 375, 461-462.	6.3	4
233	Integrating pharmacology and clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 787-790.	1.1	4
234	Finding a VOICE for UK clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 843-845.	1.1	4

#	ARTICLE	IF	CITATIONS
235	Benefits and Harms in Pivotal Trials of Oral Centrally Acting Antiobesity Medicines: A Systematic Review and Meta-Analysis. <i>Obesity</i> , 2018, 26, 513-521.	1.5	4
236	Combining and converting groups when extracting data for meta-analysis. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 85-87.	1.7	4
237	A sensitive high-temperature electrothermal atomic absorption analysis for Rb ⁺ in erythrocytes and plasma of normal and hypertensive persons. <i>Clinical Chemistry</i> , 1985, 31, 274-6.	1.5	4
238	CARE guidelines for case reports: explanation and elaboration document. Translation into Russian. <i>Digital Diagnostics</i> , 2022, 3, 16-42.	0.3	4
239	The effect of oral salbutamol on cation transport measured in vivo in healthy volunteers.. <i>British Journal of Clinical Pharmacology</i> , 1990, 30, 383-390.	1.1	3
240	Reversal of the effects of a low extracellular potassium concentration on the number and activity of Na ⁺ /K ⁺ pumps in an epstein-barr virus-transformed human lymphocyte cell line. <i>Biochemical Pharmacology</i> , 1992, 43, 489-496.	2.0	3
241	Effects of High External Concentrations of K ⁺ on ⁸⁶ Rb ⁺ Efflux in Human Platelets: Evidence for Na ⁺ /K ⁺ /2Cl ⁻ Co-Transport. <i>Clinical Science</i> , 1996, 91, 725-731.	1.8	3
242	Francis Galton and the invention of terms for quantiles. <i>Journal of Clinical Epidemiology</i> , 2001, 54, 1191-1194.	2.4	3
243	Citation classics in the <i>British Journal of Clinical Pharmacology</i> , 1974-2003. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, S699-S702.	1.1	3
244	The Diagnosis of Art: Melancholy and the Portrait of Dr Gachet. <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 373-374.	1.1	3
245	The diagnosis of art: melancholy and the Portrait of Dr Gachet. <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 373-374.	1.1	3
246	Towards a single VOICE for European clinical pharmacology: proposals for future developments. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1981-1984.	0.8	3
247	Toward standardized reporting of drug interactions: the READI checklist for anecdotal reports. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 399-409.	1.3	3
248	A brief history of clinical evidence updates and bibliographic databases. <i>Journal of the Royal Society of Medicine</i> , 2018, 111, 292-301.	1.1	3
249	The British Pharmacological Society's WDM Paton Memorial Lecture 2019: How doctors were informed about pharmaceutical products through advertising in the <i>British Medical Journal</i> from 1955/6 to 1985/6. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1901-1906.	1.1	3
250	Sodium valproate: who knew what and when? Cumulative meta-analysis gives extra insights. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 127-129.	1.7	3
251	Dealing with categorical risk data when extracting data for meta-analysis. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 43-45.	1.7	3
252	When I use a word No jab, no job? A benefit:harm balance analysis. <i>BMJ</i> , The, 2021, 375, n2934.	3.0	3

#	ARTICLE	IF	CITATIONS
253	When I use a word Medical anniversaries in 2022. <i>BMJ, The</i> , 2022, 376, o39.	3.0	3
254	When I use a word The Precautionary Principle: a definition. <i>BMJ, The</i> , 2021, 375, n3111.	3.0	3
255	When I use a word Memory, semantic and episodic. <i>BMJ, The</i> , 2022, 376, o804.	3.0	3
256	In vivo cation transport during short-term and long-term digoxin therapy.. <i>British Journal of Clinical Pharmacology</i> , 1986, 22, 27-30.	1.1	2
257	The effect of nifedipine on the disposition of strontium gluconate used as a kinetic marker for calcium in healthy volunteers.. <i>British Journal of Clinical Pharmacology</i> , 1991, 32, 441-445.	1.1	2
258	A Dictionary of Pharmacology and Allied Topics (2nd edition). <i>Trends in Pharmacological Sciences</i> , 1999, 20, 125.	4.0	2
259	Drugs and Renal Insufficiency. <i>Surgery</i> , 2003, 21, 104a-104e.	0.1	2
260	Features of this month's Journal. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 1-2.	1.1	2
261	Moving about. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 263-264.	1.1	2
262	Today's science, tomorrow's medicines. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 1-4.	1.1	2
263	The diagnosis of art: Valentin le d'Amboise and Ehlers-Danlos syndrome. <i>Journal of the Royal Society of Medicine</i> , 2007, 100, 193-194.	1.1	2
264	An agenda for research on adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 119-121.	1.1	2
265	Selected National Pharmacovigilance Websites. <i>Drug Safety</i> , 2012, 35, 141-148.	1.4	2
266	The adverse effects of nitrous oxide. <i>Adverse Drug Reaction Bulletin</i> , 2014, 285, 1099-1102.	0.6	2
267	Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1328-1337.	0.9	2
268	Introducing the EBM Verdict: research evidence relevant to clinical practice. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 85-86.	1.7	2
269	Medical Devices: Classification and Analysis of Faults Leading to Harms. <i>Drug Safety</i> , 2020, 43, 95-102.	1.4	2
270	Extracting data from diagnostic test accuracy studies for meta-analysis. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 19-21.	1.7	2

#	ARTICLE	IF	CITATIONS
271	When I use a word . . . Taking therapeutic care. BMJ, The, 2021, 375, n3010.	3.0	2
272	When I use a word . . . New medical words 1422â€“1972. BMJ, The, 2022, 376, o187.	3.0	2
273	When I use a word . . . Medical words newly logged in the OED in September 2021. BMJ, The, 2022, 376, o255.	3.0	2
274	When I use a word . . . Diagnosis. BMJ, The, 2022, 376, o747.	3.0	2
275	When I use a word . . . Counterfactual medical history: Miltonâ€™s blindness. BMJ, The, 0, , o1441.	3.0	2
276	When I use a word . . . Too much medicine. BMJ, The, 0, , o1775.	3.0	2
277	Lack of effect of phenytoin on functions related to Na ⁺ ,K ⁺ â€“ATPase activity of the intact erythrocytes of epileptic patients.. British Journal of Clinical Pharmacology, 1981, 12, 79-81.	1.1	1
278	Cardiac glycosides and drugs used in dysrhythmias. Side Effects of Drugs Annual, 1983, 7, 193-209.	0.6	1
279	Cardiac glycosides and drugs used in dysrhythmias. Side Effects of Drugs Annual, 1984, 8, 174-181.	0.6	1
280	Features of this month's Journal. British Journal of Clinical Pharmacology, 2003, 55, 223-224.	1.1	1
281	Features of this month's Journal. British Journal of Clinical Pharmacology, 2003, 56, 141-142.	1.1	1
282	Internationality. British Journal of Clinical Pharmacology, 2005, 59, 1-4.	1.1	1
283	The Diagnosis of Art: Exophthalmosâ€™Gustave DorÃ©'s Ogre. Journal of the Royal Society of Medicine, 2006, 99, 421-421.	1.1	1
284	The Diagnosis of Art: Diastrophic Dysplasia and Hephaistos. Journal of the Royal Society of Medicine, 2006, 99, 584-585.	1.1	1
285	The Diagnosis of Art: Rachmaninov's Hand Span. Journal of the Royal Society of Medicine, 2006, 99, 529-530.	1.1	1
286	Medicines and the media. British Journal of Clinical Pharmacology, 2006, 61, 121-122.	1.1	1
287	Monitoring for harms of therapy. British Journal of Clinical Pharmacology, 2006, 61, 365-366.	1.1	1
288	Editors' review of 2006 and the BJCP prize. British Journal of Clinical Pharmacology, 2007, 63, 1-4.	1.1	1

#	ARTICLE	IF	CITATIONS
289	Evaluation of pharmacological evidence for forensic purposes. <i>International Journal of Risk and Safety in Medicine</i> , 2012, 24, 3-12.	0.3	1
290	Management of pain during injection of propofol. <i>Adverse Drug Reaction Bulletin</i> , 2014, 287, 1107-1110.	0.6	1
291	A licence to cure. <i>BMJ, The</i> , 2015, 350, h1723-h1723.	3.0	1
292	What evidence affects clinical practice? An analysis of Evidence-Based Medicine commentaries. <i>Evidence-Based Medicine</i> , 2017, 22, 197-197.	0.6	1
293	Extending anticoagulation treatment for unprovoked venous thromboembolism. <i>BMJ Evidence-Based Medicine</i> , 2020, 25, 184-186.	1.7	1
294	Forgotten Primodos story and the roles of general practitioners. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 79-81.	1.7	1
295	Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-218.	0.4	1
296	Being wholistic. <i>Focus on Alternative and Complementary Therapies</i> , 2003, 8, 381-382.	0.1	1
297	How a VOICE for clinical pharmacology turns into a RECIPE for its development. <i>Translational and Clinical Pharmacology</i> , 2016, 24, 1.	0.3	1
298	When I use a word The efficiency paradox. <i>BMJ, The</i> , 2021, 375, n2712.	3.0	1
299	When I use a word Lexicographical anniversaries. <i>BMJ, The</i> , 2022, 376, o105.	3.0	1
300	When I use a word St Bartholomewâ€™onomastics and reputation. <i>BMJ, The</i> , 2022, 376, o370.	3.0	1
301	When I use a word Medical patronymics, metonymics, and papponymics. <i>BMJ, The</i> , 2022, 376, o437.	3.0	1
302	Blood pressure meta-analysis highlights an implementation gap. <i>Lancet, The</i> , 2022, 399, 1379-1380.	6.3	1
303	When I use a word Remembrance of things past. <i>BMJ, The</i> , 2022, 377, o873.	3.0	1
304	Monitoring Cholesterol-Modifying Interventions. , 0, , 245-253.		1
305	When I use a word Medical magic. <i>BMJ, The</i> , 2022, 377, o1092.	3.0	1
306	When I use a word Counterfactual medical history: the death of Charles II. <i>BMJ, The</i> , 0, , o1345.	3.0	1

#	ARTICLE	IF	CITATIONS
307	When I use a word . . . Counterfactual medical history: Milton's treatment. BMJ, The, 0, , o1505.	3.0	1
308	A tribute to Graham Dukes. Side Effects of Drugs Annual, 2000, 23, xxiii-xxvi.	0.6	0
309	Disco dancing. Cytopathology, 2002, 13, 326-327.	0.4	0
310	The British Journal of Clinical Pharmacology Editors's Report for 2002. British Journal of Clinical Pharmacology, 2003, 55, 329-330.	1.1	0
311	Features of this month's Journal. British Journal of Clinical Pharmacology, 2003, 56, 475-476.	1.1	0
312	Features of this month's Journal. British Journal of Clinical Pharmacology, 2003, 56, 347-348.	1.1	0
313	Features of this month's Journal. British Journal of Clinical Pharmacology, 2003, 56, 247-248.	1.1	0
314	Features of this month's Journal. British Journal of Clinical Pharmacology, 2003, 55, 327-328.	1.1	0
315	Features of this month's Journal. British Journal of Clinical Pharmacology, 2003, 55, 493-494.	1.1	0
316	The British Journal of Clinical Pharmacology Editors' Report for 2003. British Journal of Clinical Pharmacology, 2004, 57, 538-539.	1.1	0
317	Write on. British Journal of Clinical Pharmacology, 2005, 59, 141-142.	1.1	0
318	Editors' Report 2004. British Journal of Clinical Pharmacology, 2005, 60, 5-6.	1.1	0
319	The Doctor in Literature: Satisfaction or Resentment?. Health Expectations, 2006, 9, 196-197.	1.1	0
320	Editors' Report 2005. British Journal of Clinical Pharmacology, 2006, 61, 492-493.	1.1	0
321	Editors' Report for 2006. British Journal of Clinical Pharmacology, 2007, 64, 253-254.	1.1	0
322	When I use a word ... Innovations--'The Births of Time'. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 1037-1039.	0.2	0
323	David Grahame Grahame'smith. British Journal of Clinical Pharmacology, 2012, 73, 830-832.	1.1	0
324	Photosensitivity reactions and skin tumours associated with voriconazole. Adverse Drug Reaction Bulletin, 2015, 290, 1119-1122.	0.6	0

#	ARTICLE	IF	CITATIONS
325	Adverse events in patients taking cephalosporins versus placebo for any indication. The Cochrane Library, 2016, , .	1.5	0
326	Single or dual antiplatelet therapy after a transient ischaemic attack or minor ischaemic stroke?. BMJ Evidence-Based Medicine, 2019, 24, 196-197.	1.7	0
327	When I use a word Examining the efficiency paradox. BMJ, The, 2021, 375, n2856.	3.0	0
328	When I use a word Vaccinationâ€™rights and duties. BMJ, The, 2022, 376, o317.	3.0	0
329	When I use a word Medical trigger warnings. BMJ, The, 2022, 376, o579.	3.0	0
330	When I use a word Bioscience journalsâ€™an open and shut case?. BMJ, The, 2022, 376, o536.	3.0	0
331	When I use a word Medical aphorisms. BMJ, The, 2022, 377, o934.	3.0	0
332	Good Practice in Delivering Laboratory Monitoring. , 0, , 166-178.		0
333	Monitoring Intraocular Pressure in Glaucoma. , 0, , 325-334.		0
334	Monitoring the Initial Response to Treatment. , 0, , 75-89.		0
335	When I use a word Medical hyacinths. BMJ, The, 2022, 377, o1036.	3.0	0
336	When I use a word More medical magic. BMJ, The, 2022, 377, o1154.	3.0	0
337	When I use a word Some words about the climate. BMJ, The, 2022, 377, o1222.	3.0	0
338	When I use a word Medical counterfactuals. BMJ, The, 0, , o1267.	3.0	0
339	When I use a word Medical words of 1952â€™a jubilee celebration. BMJ, The, 0, , o1394.	3.0	0
340	When I use a word Counterfactual medical history: Miltonâ€™s poetry. BMJ, The, 0, , o1569.	3.0	0
341	When I use a word Values. BMJ, The, 0, , o1636.	3.0	0
342	When I use a word Unnecessary, hateful, sickening words. BMJ, The, 0, , o1693.	3.0	0